Immunotherapy combo before chemo-radiation shows promise for esophageal cancer
NCT ID NCT03044613
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemoradiation, followed by surgery. The goal is to see if this approach changes the tumor's environment and improves survival without causing major delays in surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alleghany Health Network
Pittsburgh, Pennsylvania, 15212, United States
-
Baylor University/ Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can surgery for stomach or esophageal cancer cloud the mind?